Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess [PDF]
Frontiers in Pharmacology, 2023 Introduction: Tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etanercept, golimumab, and certolizumab pegol) have revolutionized the treatment of severe immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn’s ...
Hongbo Zhou, Ruxu You, You Ruxu
exaly +4 more sources
Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess [PDF]
Frontiers in PharmacologyBackgroundThis study assessed the adverse drug reactions (ADRs) associated with HDAC inhibitors using the VigiAccess database maintained by the World Health Organization (WHO).
Yumeng Lin, Lin Yumeng
exaly +4 more sources
Real-world safety of tirofiban: a disproportionality analysis using data from FAERS and WHO-VigiAccess [PDF]
Frontiers in PharmacologyObjectiveThis study aimed to detect tirofiban-related adverse event (AE) signals using the FAERS and WHO-VigiAccess databases to support safer clinical use.MethodsAll tirofiban-related AE reports were retrieved from FAERS (2004Q1 to 2024Q4) and WHO ...
Zheng Yifan
exaly +4 more sources
Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess [PDF]
Frontiers in PharmacologyIntroductionFinerenone is a novel non-steroidal mineralocorticoid receptor antagonist that has shown promise in the treatment of chronic kidney disease and heart failure.
Boda Zhou, Zhou Boda
exaly +4 more sources
Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess [PDF]
Frontiers in PharmacologyIntroductionAntitumor medications such as Avastin, Berubicin, and Temozolomide have fundamentally transformed the treatment landscape for gliomas by exhibiting potent pharmacological effects on both high-grade and low-grade gliomas.
Huadong Ke +7 more
exaly +4 more sources
DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess [PDF]
Frontiers in PharmacologyIntroductionDNA methylation inhibitors (azacitidine, decitabine) have revolutionized the treatment dilemma of myelodysplastic syndromes (MDS), a group of malignant hematopoietic disorders.
Wang Haojie
exaly +4 more sources
The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases [PDF]
Frontiers in PharmacologyBackgroundAzacitidine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It acts as a cytosine analog and DNA methyltransferase inhibitor, inducing DNA hypomethylation to reverse epigenetic modifications and restore normal ...
Ding Juan, Guo Linlin, Linlin Guo
exaly +4 more sources
Adverse event profile of lomustine and temozolomide: a descriptive analysis from WHO-VigiAccess [PDF]
Frontiers in PharmacologyIntroductionIn gliomas, various oncogenic factors can lead to an imbalance between cell proliferation and apoptosis. Lomustine inhibits tumor cell growth by disrupting DNA replication and repair mechanisms.
Hua Luo, Liwei Zhang, Luo Hua
exaly +4 more sources
A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases [PDF]
Frontiers in PharmacologyBackgroundLecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence.
Haoxiang Hu +6 more
exaly +4 more sources
Assessing the real-world safety of fenofibric acid for hyperlipidemia: results from WHO-VigiAccess and FAERS databases [PDF]
Frontiers in MedicineBackgroundFenofibric acid is a small-molecule fibrate that functions as an agonist of peroxisome proliferator-activated receptor alpha (PPARα) and serves as an inhibitor of liver fatty acid-binding protein.
Yaxing Li +8 more
exaly +4 more sources